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Abstract
Background—RNA-directed regulation of epigenetic processes has recently emerged as an 
important feature of mammalian differentiation and development. Perturbation of this regulatory 
system in the brain may contribute to the development of neuropsychiatric disorders.
Methods—RNA sequencing (RNA-seq) was used to identify changes in the experience-
dependent expression of long non-coding RNAs (lncRNAs) within the medial prefrontal cortex 
(mPFC) of adult mice. Transcripts were validated by real-time quantitative PCR and a candidate 
lncRNA, Gomafu, was selected for further investigation. The functional role of this schizophrenia-
related lncRNA was explored in vivo by antisense oligonucleotide-mediated gene knockdown in 
the mPFC, followed by behavioral training and assessment of fear-related anxiety. LncRNA-
directed epigenetic regulation of gene expression was investigated by chromatin and RNA 
immunoprecipitation assays.
Results—RNA-seq analysis revealed changes in the expression of a significant number of genes 
related to neural plasticity and stress, as well as the dynamic regulation of lncRNAs. In particular, 
we detected a significant down-regulation of Gomafu lncRNA. Our results revealed that Gomafu 
plays a role in mediating anxiety-like behavior, and suggest that this may occur through an 
interaction with a key member of the polycomb repressive complex 1, BMI1, which regulates the 
expression of the schizophrenia-related gene beta crystallin (Crybb1). We also demonstrated a 
novel role for Crybb1 in mediating fear-induced anxiety-like behavior.
Conclusion—Experience-dependent expression of lncRNAs plays an important role in the 
epigenetic regulation of adaptive behavior, and the perturbation of Gomafu may be related to 
anxiety and the development of neuropsychiatric disorders.
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Introduction
Once considered vestiges of our evolutionary history associated with “junk” DNA, non-
coding transcriptional activation, and post-transcriptional gene silencing (1-5). Advances in 
RNA sequencing (RNA-seq) technology have resulted in the discovery of a large number of 
long ncRNAs (lncRNAs) (6-11), many of which show features of functionality (12-14). 
There are at least 50,000 genes specifying lncRNAs scattered throughout the human 
genome, with many expressed in a highly cell type- and developmental stage-specific 
manner (15-20). Moreover, a significant number of brain-enriched or brain-specific 
lncRNAs are found adjacent to genes encoding transcriptional regulators and key drivers of 
neural development (21), including those involved in the regulation of stem cell 
pluripotency, neuronal differentiation, and synaptogenesis (16, 18, 22-24).
In agreement with these findings, lncRNAs have been implicated in neurodevelopmental 
disorders such as Rett syndrome (25), autism (26, 27), schizophrenia (SZ) (28, 29) and 
Fragile X syndrome (30). Screening of lncRNA activity has also shown links between 
lncRNA expression and drug abuse (31, 32), suicidal behavior (33) and potentially anxiety 
disorders. For instance, it has been reported that experimental knockdown BC1 leads to 
increased anxiety-like behavior in mice (34, 35).
Recent evidence indicates that the expression of lncRNAs can be altered in an activity-
dependent manner (29, 36). LncRNAs have been found to be co-expressed with activity-
dependent genes such as C-fos, Arc, Nr4a2 and Bdnf, suggesting a coordinated network of 
coding and non-coding gene expression associated with neuronal plasticity (29, 36, 37).
Despite these correlative links, little is known about the expression and function of brain 
lncRNAs, nor the mechanisms by which these transcripts influence protein-coding gene 
expression within the context of neuropsychiatric disease. Here we combined high-
throughput RNA-seq with molecular and behavioral approaches to identify changes in the 
expression of lncRNAs. We also determined whether these changes contribute to the 
epigenetic regulation of gene expression underlying the development of anxiety disorders.
Materials and Methods
Animals
Naïve 9-week-old C57BL/6 male mice were housed individually in sections of divided 
cages, with free access to food and water under a 12h light/dark cycle in a humidity- and 
temperature-controlled vivarium. Behavioral tests were conducted during the light cycle, 
and all procedures were performed with approval from the Animal Ethics Committee of The 
University of Queensland.
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Fear conditioning
For tissue collection and sequencing library preparation, 3 groups (n=8 per group) of mice 
were used: a naïve, age-matched, home-cage control group, a fear-conditioned group that 
received six pairings of a 2 min 80 dB white noise conditioned stimulus (CS) that co-
terminated with a 1 s foot-shock at 0.7 mA as the unconditioned stimulus (US, inter-trial 
interval of 2 min), and a context only group that was exposed to the CS but not the US. 
Animals were sacrificed 90 min post-training, followed by medial prefrontal cortex (mPFC) 
dissection and nuclear-enriched RNA extraction. To determine the effect of Gomafu 
knockdown on fear conditioning, animals were infused with 600nM of a Gomafu antisense 
oligonucleotide (ASO), directly into the mPFC, whereas the control group received an 
infusion of a scrambled control. 3h after infusion, mice were trained using a mild fear 
acquisition protocol in order to avoid a non-specific response (3 CS-US pairing with foot 
shocks of 0.4mA), followed by a 2CS test for memory recall in the same context 24h later.
Measures of anxiety
Anxiety tests for the knockdown and control groups were performed 3h after ASO infusion, 
and 2 weeks after lentiviral infusion respectively, and involved the use of mild stressors 
(38). This included a 10min exposure to a 27x27x20.3cm open field chamber with 200 lux 
of light intensity, which was followed by an interval of 30min. Mice were then introduced 
for 10min into an elevated plus maze (under bright light at 900 lux in the open arms and 200 
lux in the closed arms), and the time spent in the open arms was recorded. Following a 
second interval of 10min mice were once more placed in the open field for 10min, at which 
point time in the center was automatically determined in seconds, while ambulatory time, 
distance traveled and self-grooming time were calculated as a ratio between zone results.
Stereotaxic surgery and cannula implantation
Mice were anesthetized with ketamine (100 mg/kg) and xylazine (10mg/kg). Surgeries were 
performed under stereotaxic guidance and cannulas were implanted bilaterally within the 
prelimbic region of the PFC (PLPFC) at +1.8mm anterioposterior and −2mm dorsoventral to 
Bregma. Mice were allowed to recover for a minimum of 7 days before experiments. 
Animals were transcardially perfused post-training with cold phosphate buffered saline 
(PBS) (Lonza, Walkersville, MD, USA), followed by 4% paraformaldehyde in PBS. Brains 
were dissected out, sectioned and the localization of the ASO and shRNA infusion was 
determined by fluorescence microscopy.
Nuclear enrichment, RNA extraction and reverse transcription
mPFC derived from fear-conditioned mice was homogenized in nuclear buffer (detailed in 
Supplement 1) followed by RNA extraction using the RNAeasy Mini kit (Qiagen, Hilden, 
Germany). Reverse transcription and cDNA synthesis was performed following the 
Quantitech Reverse Transcription kit protocol (Qiagen, Hilden, Germany), with the 
exception of RNA eluted from RNA immunoprecipitation (RIP) assays, which was reverse 
transcribed using Super Script III First Strand Synthesis (Invitrogen, Carslbad, CA, USA). 
The assay was validated both in vitro and in vivo (Fig S6 A-B in Supplement 1).
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RNA sequencing
1μg of nuclear-enriched RNA, with a minimum RNA Integrity (RIN) value of 8, from 6 
samples per treatment was used to build a total RNA library using the Illumina TruSeq 
RNASample Preparation v2 protocol. Each animal was individually indexed, representing a 
single library per mouse, which was further multiplexed in 2 pools of 9 animals before 
loading into the Illumina flow cell. Samples with low read alignment were excluded, 
resulting in 5 animals for Naïve and Context groups and 4 mice for FC. The quality of the 
RNA library was verified on an Agilent DNA 1000 chip and run on the Bioanalyzer, while 
quantification was determined by qPCR, after which the samples were sequenced using the 
Illumina HiSeq v3 platform.
Bioinformatic analysis
Mapping of reads to the mouse genome (mm10) was performed using the Bowtie2 and 
TopHat 2.0.6 programs (39). Cufflinks 2.0.2 (BETA) algorithms were then implemented for 
assembly of RNA sequencing reads into transcripts and analysis of differential levels of 
transcript expression among treatment groups as previously described (40, 41). For the 
purpose of this investigation we used a cutoff of p<0.03.
Gene knockdown
ASOs targeting Gomafu lncRNA were designed using the IDT Antisense design software 
targeting the splicing regulatory regions known as exonic splicing enhancers, as well as 
sequences with higher G and C content and low potential for RNA secondary structure 
formation. Primer sequences are detailed in Table S4 (Supplement 1). ShRNAs 
(Genecoepoa) targeting Crybb1 mRNA were packaged in-house using a 3rd generation 
lentiviral packaging system.
Primary neurons cell culture and electroporation
Cortical neuronal cells were dissociated from C57BL/6 mouse embryos at embryonic day 16 
and plated onto poly-L-ornithine hydrochloride-coated plates. Cultures were grown in 
Neurobasal medium (GIBCO Life Technologies, NY, USA) containing 5% fetal bovine 
serum, 1% penicillin/streptomycin, 1% GlutaMAX, and 2% B27 supplement (GIBCO Life 
Technologies, NY, USA), and were maintained at 37°C with 5% CO2. Electroporation of 
ASOs was performed using the Nucleofector transfection system (Lonza, Basel, 
Switzerland) according to the manufacturer’s instructions. KCl treatments were performed at 
50mM concentration.
Technical validation of RNA sequencing gene target selection
Gene expression was measured using the SYBR Green quantitative real-time PCR (qRT-
PCR) detection method on a RotorGene 3000 (Qiagen, Hilden, Germany). The 2^-AACt 
method was applied to estimate differential levels of gene expression. ANOVA and Holm-
Sidak’s multiple comparison tests were applied to establish gene expression differences 
among groups. Validation was performed with the original RNA used for RNA-seq.
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Chromatin immunoprecipitation (ChIP)
Dissociated cortical neurons were subjected to electroporation with 200nM ASO for 
Gomafu knockdown followed by BMI1 pull-downs 3h post-transfection. For in vivo studies, 
tissues were dissected out and homogenized 1.5h after training. Tissue and cells were 
processed as previously described (42). Chromatin was immunoprecipitated using 4 μg 
ChIP-grade antibodies specific to BMI1 (1T21, Abcam, Cambridge, England, United 
Kingdom), SUZ12 (ab12073, Abcam, Cambridge, England, United Kingdom), and RING1B 
(D22F2, Cell Signaling, Danvers, Massachusetts, USA), H2AK119 (D2764, Cell Signaling, 
Danvers, Massachusetts, USA), mouse IgG (103533, Active Motif, Carslbad, CA, USA) and 
rabbit IgG (2295402, Millipore, Billerica, Massachusetts, USA). DNA-protein interactions 
were analyzed by qRT-PCR using primers specific to the binding motifs of the proteins 
being investigated.
RNA immunoprecipitation (RIP)
Naïve tissues were dissected out and homogenized followed by fixation and cross-linking. 
Immunoprecipitation with 4 μg of the antibody of interest was performed as previously 
described (22), and RNA was extracted using the Trizol method (Ambion, Carslbad, CA, 
USA), followed by DNase treatment using the TURBO DNA-free Ambion kit (Ambion, 
Carslbad, CA, USA).
Results
Long non-coding RNAs are dynamically expressed in the mPFC in response to behavioral 
experience
Fear-conditioned mice exhibited a robust increase in fear-related behavior at the end of 
training compared to context-only exposed mice (Fig. S1A in Supplement 1). Nuclear RNA 
was extracted from the mPFC of mice sacrificed 90 min after behavioral training, and 
transcriptome-wide profiles were obtained by RNA-seq. In total, we detected more than 400 
loci that exhibited differential expression of protein-coding and non-coding RNAs (Fig. 1A). 
A complete list of differentially expressed transcripts identified by RNA-seq is provided in 
Table S1 in Supplement 2.
Intergenic lncRNAs from 53 loci were identified as being significantly altered in either 
context-exposed or fear-conditioned mice, with the majority of these transcripts being found 
within 100kb of the nearest protein-coding gene, consistent with a potential cis-regulatory 
function (21, 43) (Fig. 1B-E; Table S2 in Supplement 1). RNA-seq analysis also revealed a 
cluster of modulated protein-coding genes, some of which have been implicated in 
behavioral regulation, in mediating the stress response, and in neuropsychiatric disorders 
(Table S3 in Supplement 1).
Experience-dependent alterations in lncRNA expression within the mPFC
In order to validate the RNA-seq findings, candidates were selected for downstream 
analyses. We first examined the expression of two protein-coding genes, Bdnf (exon IV) and 
Homer1, which are involved in neural plasticity and memory (Table S3 in Supplement 1; 
Fig. 2A and B). Bdnf has been reviewed as the master regulator of neuronal circuitries 
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driving learning and synaptic plasticity (44). This gene has a complex structure that allows 
its differential epigenetic response to stimuli (45, 46); however, Bdnf exon IV has 
particularly been shown to participate in memory processes within the mammalian PFC 
(47). There was a significant increase in Bdnf exon IV and Homer1 mRNA expression in 
context-exposed mice, confirming previous studies demonstrating the activity-dependent 
nature of these genes in models of experience-dependent plasticity.
We further observed a significant decrease in the expression of the activity-dependent 
immediate early gene Npas4 (Fig. 2C). Although Npas4 expression is related to fear 
learning, a down-regulation of this gene is correlated with both exposure to stress and 
impairments in the formation of fear memory (48-51). Indeed, stressors can also lead to fear 
incubation or enhanced fear-potentiated startle, which may be related to anxiety rather than 
learning per se (52-54). In the experiments described here, we used a strong fear 
conditioning protocol (6CS-US pairings of a 0.7mA foot shock), which we expected could 
lead to an increase in stress reactivity and anxiety. In this paradigm, fear-conditioned mice 
showed high levels of freezing, not only during CS onset but also during the inter-trial 
interval (Fig. S1 A and B in Supplement 1).
Concordantly, we also observed an increase in the expression of the stress- and anxiety-
related gene, Hsp901b, following fear conditioning (Fig. 2D). Although there was no effect 
of fear conditioning on the expression of the synaptogenesis-related lncRNA Malat1 (Fig. 
2E), two intergenic lncRNAs of unknown function exhibited a significant, but non-specific, 
decrease in expression following behavioral training (Fig. 2F and G). The first of these, 
Gm21781, is upstream of a gene that encodes a DNA binding protein known as zinc finger 
and BTB domain containing 2 (Zbtb2), which has been shown to be a potent epigenetic 
regulator (55), and the second, Gm11762, is antisense to neuronal pentraxin 1 (Nptx1), 
which has been reported to enhance synaptogenesis and glutamate signalling through 
clustering of AMPA receptors (56). Finally, we observed a significant down-regulation of 
the neuropsychiatric disease-related lncRNA Gomafu in the mPFC, which occurred 
following fear conditioning but not after context exposure (Fig. 2H). Importantly, the down-
regulation of Gomafu in fear-conditioned animals was also observed in a targeted RNA-seq 
experiment performed in these mice (Fig. S2A in Supplement 1) using a recently developed 
highly sensitive RNA capture protocol (57), thereby confirming the previously reported 
activity-dependent nature of the expression of this lncRNA (29). Together these data suggest 
that experience-induced regulation of lncRNAs may play a role in regulating neuronal 
plasticity and cognitive processes in the adult brain.
ASO-mediated knockdown of Gomafu within the mPFC induces anxiety-like behavior
In order to determine whether Gomafu regulates adaptive behavior, we employed an ASO-
mediated knockdown approach. The efficacy of an ASO designed to specifically target 
Gomafu (Gomafu KD) was first tested in cultured primary cortical neurons at different time 
points (Fig. S3A and B in Supplement 1). The preliminary screening indicated an 
approximately 50% knockdown at a concentration of 1μM, when measured 3h post-
administration (Fig. 3A), which decreased further by 6h post-infusion (Fig. S3A and B in 
Supplement 1).
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ASO-mediated Gomafu KD also produced a high rate of neuronal transfection when infused 
directly into the PLPFC in vivo (Fig. 3B) prior to fear conditioning, and was preliminarily 
verified by gene expression assay compared to a saline and a scrambled control group (Fig. 
S4A and B in Supplement 1). Following a mild fear-conditioning protocol, mice infused 
with ASO-mediated Gomafu KD exhibited a moderate but significant enhancement in 
freezing behavior (Fig. 3C). However, 24h later these mice did not demonstrate a difference 
in fear recall of the previous conditioning episode, when compared to the control group, 
indicating there was no effect of Gomafu on long-term memory per se (Fig. 3D).
Given that stress-induced anxiety has been shown to enhance fear responding and interfere 
with memory retrieval events (58-61), we also examined the effect of Gomafu KD on 
anxiety-like behavior in an independent cohort of mice. Infusion of ASO-mediated Gomafu 
KD into the PLPFC led to a decrease in the amount of time spent in the center of an open 
field (Fig. 4A and E), which was accompanied by a significant increase in distance traveled 
(Fig. 4B), ambulatory time (Fig. 4C), and stereotypic grooming behavior (Fig. 4D), all of 
which are characteristic features of increased anxiety in mice (62). These data suggest that a 
reduction in the expression of the lncRNA Gomafu in the mPFC promotes behaviors that 
have been implicated in the development of anxiety disorders.
A dual role for the neuropsychiatric-disease related lncRNA Gomafu
LncRNAs have been shown to exert dual control over gene expression through both cis- and 
trans-mediated mechanisms (63-65). As indicated above, the majority of lncRNAs that were 
differentially expressed in an experience-dependent manner were encoded within 100kb of 
the nearest protein-coding gene, suggesting that these experience-dependent lncRNAs may 
control gene expression via a cis-mediated mechanism. Given that the activity-dependent 
lncRNA Gomafu was down-regulated in the mPFC following behavioral training, and that it 
has previously been shown to regulate alternative splicing associated with neuropsychiatric 
disease through a trans-mediated mechanism (29), we examined whether this lncRNA also 
regulates gene expression associated with fear-induced anxiety.
Crystallin clusters are molecular chaperone proteins belonging to the heat shock family of 
genes, and are known to play a major role in maintaining cellular homeostasis in response to 
stress (66-68). While the alpha-beta cluster has been associated with neurodegenerative 
diseases (69, 70), a beta family member, Crybb1, has been reported to exert a major effect 
over these crystallin clusters by acting as an intermolecular chaperone that regulates their 
correct folding and misfolding (71). Furthermore, Crybb1 has previously been associated 
with SZ and stress (72-75). In contrast to Gomafu, fear conditioning led to a significant and 
specific increase in the level of Crybb1 mRNA (Fig. 5A), with no change being observed 
with its close homolog, Cryba4, which is located on the same strand as Gomafu (Fig. S2 in 
Supplement 1).
In order to test the hypothesis that Gomafu exerts its influence on proximal gene expression 
via a cis-mediated mechanism, we employed a model of primary cortical neurons in vitro. 
As expected, infusion of ASO-mediated Gomafu KD in primary cortical neurons led to a 
significant increase in Crybb1 mRNA expression (Fig. 5B). Next, considering that members 
of the polycomb repressive complex (PRC) have been shown to interact with lncRNAs to 
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affect gene expression (22, 76-80), we explored the relationship between Gomafu and major 
components of PRC1 and PRC2, namely BMI1 and RING1B and SUZ12 respectively. The 
binding motifs for these molecules have been identified (81, 82) and were present within 
2kb of the transcription start site (TSS) of Crybb1, and within the gene body of Gomafu 
(Fig. 5C). RNA immunoprecipitation using an antibody specific to BMI1 revealed an 
interaction with Gomafu lncRNA (Fig. 5D). In contrast, there was no significant interaction 
between Gomafu and the PRC2 components SUZ12 and RING1B (Fig. 5E). In addition, no 
interaction was observed between a U6 negative control and these proteins (Fig. 5E), further 
supporting the presence of a specific interaction between Gomafu and BMI1.
We further verified through in vitro ChIP assay an activity-dependent binding of the PRC1 
proteins BMI1 and RING1B accompanied by the ubiquitin histone 2A lysine 119 repressive 
mark within the Crybb1 promoter, which was released upon KCl-induced depolarization 
(Fig. 5F). Although binding of the PRC2 component SUZ12 was observed, the interaction 
was unresponsive to stimulation (Fig. 5F), confirming the specific activity-dependent 
recruitment of PRC1 to the Crybb1 promoter.
To test whether Gomafu is required for the interaction between BMI1 and Crybb1, we 
performed a Gomafu knockdown experiment in cortical neurons, followed by ChIP analysis. 
After transfection with an ASO targeting Gomafu KD, there was a significant decrease in 
BMI1 occupancy at the Crybb1 promoter (Fig. 5G). However, importantly, there was no 
effect of the knockdown on SUZ12 occupancy (Fig. 5G). This finding is consistent with the 
idea that, under basal conditions, BMI1 is maintained at the Crybb1 promoter through a 
direct interaction with Gomafu, which serves to repress the transcriptional activity of 
Crybb1.
To investigate the interaction between BMI1 and Crybb1 in vivo, similar ChIP analyses 
were performed which revealed BMI1 occupancy at the proximal promoter of Crybb1 in 
mPFC tissue obtained from naïve animals. Although not significant, a marked decrease was 
observed in fear-conditioned compared to naïve animals (Fig. 5H). Relative to input, there 
was little evidence of BMI1 occupancy in a region of the Crybb1 promoter distal to the 
BMI1 binding motif (Fig. 5I). These results suggest that, upon neuronal stimulation or 
behavioral training, a decrease in Gomafu releases PRC1 from the Crybb1 promoter, leading 
to an activity-dependent increase in Crybb1 mRNA expression.
A novel function for Crybb1 in the adult brain. To test the hypothesis that fear-related 
anxiety in mice is linked to Crybb1 expression, we examined the behavioral effect of 
Crybb1 knockdown (Crybb1 KD) (Fig. S5 in Supplement 1). Consistent with our Gomafu 
findings, knockdown of Crybb1 decreased anxiety-like behaviour in the activity-monitoring 
chamber (Fig. 6A and 6B). Interestingly, in the pre-training test used to induce stress in 
these subjects, mice treated with Crybb1 KD spent significantly more time in the open arms, 
also supporting the idea that decreased Crybb1 led to a decrease in anxiety (Fig. 6C). We 
therefore show that Crybb1 directed knockdown within the mPFC has a role in stress-
associated responses in mice.
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Discussion
The present findings reveal widespread experience-dependent activation of lncRNAs in the 
mPFC, including differential expression of a significant number of non-overlapping 
intergenic lncRNAs. In particular, the expression of the SZ-associated lncRNA, Gomafu, 
was decreased in the mPFC following fear conditioning, and ASO-mediated knockdown of 
this lncRNA promoted stress reactivity and anxiety-like behavior with no effect on long-
term memory.
Fear is an evolutionary programed response for self-preservation and survival, but it can also 
induce pathological behaviors fueled by the persistent memory of adverse events (83). The 
PFC is a major site mediating stress-associated disorders and can elicit an anxiety response 
in the fear-conditioning paradigm (84-86). Fear conditioning has further been demonstrated 
to induce greater anxiety-like behaviors in ‘high fear learning mouse lines’, establishing a 
direct genetic link between fear conditioning and anxiety (87). Concordantly, the PFC is also 
vulnerable to stress inducing SZ (88), and has been implicated as a likely neurological site 
for stress and anxiety behavioral responses following fear-related learning (85, 86, 89).
Consistent with our findings, Gomafu has been reported to show evidence of dysregulation 
in post mortem cortical tissue of patients who had suffered SZ (29), which is commonly 
associated with anxiety disorders (90-96). Gomafu is expressed in specific neurons, 
localized in sub-nuclear speckle-like structures (97), and has been found to be associated 
with the splicing factors SRSF1 and QK1 (29), the latter of which has been linked with SZ 
(98-100). Moreover Gomafu knockdown and overexpression affects expression and 
alternative splicing of genes associated with SZ, such as Erbb4 and Disc1 (29).
Here we have identified a potential pathway of Gomafu regulatory function through 
recruitment of the PRC1 complex to the site of gene transcription. This suggests a dual 
function of Gomafu on distal and local genes that guide epigenetic modulators in abnormal 
behaviors. It is well established that splicing is regulated by epigenetic factors (101, 102), 
possibly via the 4-dimensional organization of transcription-splicing complexes (103), 
which may themselves be built on RNA scaffolds (104). Although the mechanistic basis of 
the interaction of Gomafu with epigenetic processes has yet to be resolved, these results add 
to the emerging evidence that epigenetic function of lncRNAs may play a role in behavior 
and neurological diseases (105, 106).
We also showed that the expression of the Crybb1 gene was increased in the mPFC 
following fear conditioning and after Gomafu knockdown. Dysregulation of Crybb1 has 
been associated with SZ and autism (72) and both Gomafu and Crybb1 reside in the 
conserved human locus 22q12.1 (29), which has been related to SZ and generalized anxiety 
disorders (73-75, 107). Although it has been linked to the development of cataracts (68, 108, 
109), the specific function of Crybb1 in the adult brain has not been determined. Here, in 
conjunction with lncRNA activity, we have discovered a novel role for Crybb1 in mediating 
fear and stress-associated responses, with its repression appearing to reduce anxiety-like 
behavior in mice.
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We suggest that Gomafu, in addition to its role in regulating alternative splicing in trans 
(29), acts in cis to direct the epigenetic regulation of Crybb1. Under basal conditions, 
Gomafu maintains the PRC1 at the promoter of Crybb1, which serves to repress its 
expression. In response to neuronal activation or fear conditioning, the activity-dependent 
down-regulation of Gomafu, and its subsequent dissociation from BMI1, relieves its 
repressive control over the Crybb1 promoter, leading to increased Crybb1 gene expression 
(Fig. 7). Bmi1 has been reported to act as a major regulator of the cell stress response 
(110-113), and to sustain stem cell self-renewal in both the peripheral and central nervous 
systems (114-118). It also plays a key role in the defensive response to oxidative stress by 
affecting neuronal survival through repression of p53 (119, 120).
These results imply a complex relationship between lncRNA activity and transcriptional 
regulation in the adult brain. The dual function of Gomafu is reminiscent of previous work 
demonstrating that the lncRNA Malat1 can both function in trans, by interacting with hPSF 
protein (121) and serine/arginine splicing factors to regulate gene expression and cell cycle 
fate, respectively (63, 64), and in cis to regulate the expression of adjacent genes (65).
In summary, we have shown that the down-regulation of Gomafu lncRNA drives anxiety-
like behavior. We further propose a novel role for lncRNAs within the mPFC in directing 
the epigenetic regulation of gene expression associated with adaptive behavior. Together 
with its role in governing SZ-related alternative splicing (29), in trans, Gomafu also may 
function in cis to control gene expression and complex behavior. These findings suggest that 
further investigation into lncRNAs as molecular links between epigenetic mechanisms, and 
the development of neuropsychiatric disorders is warranted.
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Figure 1. Transcriptome-wide analysis of nuclear RNA expression in the mouse prefrontal 
cortex reveals dynamic regulation of coding genes as well as lncRNAs
(A) BioVenn graphic of loci detected by nuclear-enriched RNA-Seq with p-value (p) <0.03 
corresponding to each pairwise comparison for naïve, context exposure (Ctx) and fear 
conditioning (FC) groups. (B) Distribution analysis of lncRNA loci revealing close 
proximity to coding genes. (C, D, E) Volcano plot showing log2 fold change magnitude of 
lncRNAs with p-value <0.03 in each pairwise analysis. Up-regulation of genes in context 
(D-E) and in naïve (F) animals is shown to the right side of the 0 in each figure.
Spadaro et al. Page 18
Biol Psychiatry. Author manuscript; available in PMC 2016 December 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 2. RT-qPCR validation of plasticity-related genes and non-coding RNA transcripts
(A-D) Analyses of protein coding genes confirm up-regulation of Bdnf exon IV mRNA 
(naïve vs Ctx ***p<0.001, Kruskal Wallis test statistics 16.58), up-regulation of Homer1 
(naïve vs Ctx, *p<0.05, ANOVA, F(2, 20)=5.119), down-regulation of Npas4 (naïve vs FC, 
*p<0.05, ANOVA, F (2, 20)=5.5), and up-regulation of Hsp901b (naïve vs FC, **p<0.01, 
Kruskal Wallis test statistics 9.459). (E-G) Analyses of lncRNAs demonstrate a non-
significant slight up-regulation of Malat1, while Gm21781 lincRNA and Gm11762 lncRNA 
were down-regulated following fear conditioning relative to naïve mice (ANOVA, 
**p<0.01, F (2, 20) =7.308 and ANOVA, **p<0.01, F(2, 20)=5.892 respectively). (H) 
Specific down-regulation of Gomafu lncRNA in fear-conditioned mice (ANOVA, **p<0.01, 
F (2, 20)=5.953 naïve vs FC and Ctx vs FC). n=8 per group.
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Figure 3. Knockdown of Gomafu lncRNA in the PLPFC enhances fear response during 
behavioral training
(A) Knockdown level by Gomafu ASO was assessed in cortical neurons 3h post-transfection 
(***p<0.001, t=11.59 df=4, n=3 per group) relative to control (cntl). (B) Coronal section of 
mouse brain infused with 6-Fam fluorescein-labeled Gomafu ASO (600nM) and co-stained 
with DAPI (blue). (C) Fear acquisition profile of animals trained at 3CS-US, 3h post 
infusion (CS3: *p<0.05, t=2.672 df=12, n=6 in cntl and n=8 in ASO-induced Gomafu KD). 
(D) Recall test performed in mice 24h after the initial fear conditioning.
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Figure 4. Knockdown of Gomafu lncRNA induces anxiety-like behavior
(A and E) A mild anxiety test performed on Gomafu knockdown animals in an activity 
monitoring chamber demonstrated that significantly less time was spent in the center of the 
field (**p<0.01, t=3.922 df=16, n=9 per group). (B, C, D) Gomafu knockdown mice also 
exibited a significant tendency to travel longer distances outside the center of the field, as 
well as having an increased ambulatory and stereotypic grooming time compared to control 
animals (*p<0.05, t=2.523 df=16, n=9 per group; *p<0.05, t=2.158 df=16, n=9 per group 
and *p<0.05, Mann-Witney U 16, n=9 per group respectively).
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Figure 5. Interaction of Gomafu with the PRC1 complex in the Crybb1 promoter region leads to 
transcriptional repression
(A). In vivo RT-qPCR analysis of Crybb1 in fear conditioned (FC) and context (Ctx) mice 
showed a significant up-regulation in response to the fear stimulus relative to naïve animals 
(ANOVA *p<0.05, Kruskal-Wallis statistic 6.455, n=8 per group). (B) Significant in vitro 
up-regulation of Crybb1 resulted from ASO-mediated Gomafu KD at 1μM concentration in 
cortical neurons (***p<0.001, t=12.89 df=4, n=3 per group). (C) Schematic diagram 
showing Gomafu lncRNA and Crybb1 genomic structure and loci on chromosome 5, 
including the promoter region of Crybb1 containing the BMI1 consensus sequence. (D) In 
vivo RIP assay from mPFC tissue revealed a significant binding of BMI1 on Gomafu 
lncRNA relative to IgG in exonic region 2 (Reg 2, *p<0.05, t=2.916 df=4, n=3 per group) 
and a marked binding in the consecutive primer for exonic region 1 (Reg 1, p=0.07, t=2.434 
df=4, n=3 per group), as opposed to the negative locus on U6 RNA. (E) RIP analysis for the 
same regions containing RING1B and SUZ12 binding sites showed no significant 
enrichment compared to the negative control, U6 (n=3 per group). (F) In vitro ChIP analysis 
under basal conditions and KCl stimulation exposed a significant dysregulation of BMI1 at 
the Crybb1 promoter region, approximately 1.76kb from TSS (region 1) in KCl-treated cells 
(***p<0.001, t=6.369 df=6, n=4 per group) which was followed by down-regulation of the 
RING1B and UBH2Ak119 repressive marks (**p<0.01, t= 3.511 df=4, n=3 per group and 
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**p<0.01, t=5.426 df=4, n=3 per group respectively). No significant changes were seen in 
the same region for SUZ12. (G) In vitro ChIP analysis revealed a significant decrease in 
BMI1 binding at 1.76kb from the Crybb1 TSS, using two consecutive primers, Reg1 and 
Reg2, following ASO-mediated Gomafu KD in cortical neurons (*p<0.05, t=4.427 df=4, 
n=3 per group and at 1.35kb from TSS p=0.118, t=1.986 df=4, n=3 per group), whereas no 
changes were observed in a negative control containing the SUZ12 binding site. (H) In vivo 
ChIP analysis from mPFC tissue of trained mice showed BMI1 binding at approximately 
1.76kb from the Crybb1 TSS, which markedly decreased after fear conditioning (ANOVA, 
p=0.116, F (2,6)=3.143, n=3 per group; t-test between naïve and fear conditioned mice, 
p=0.064, n=3 per group). (I) ChIP analysis in a negative region about 1kb from the Crybb1 
TSS did not show similar regulation of BMI1 on Crybb1 (ANOVA, p=0.755, F (2, 
6)=0.2943, n=3 per group).
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Figure 6. Knockdown of Crybb1 mRNA expression decreases anxiety in mice
(A-B) An anxiety test demonstrated that Crybb1 knockdown animals (Crybb1-KD) spent 
significantly more time within the center of the activity-monitoring chamber (*p<0.05, t= 
2.559 df=12, cntl n=6, Crybb1-KD n=8) while travelling significantly shorter distances 
(**p<0.01, t= 3.263 df=12, cntl n=6, Crybb1-KD n=8). C) Crybb1 knockdown mice also 
spent significantly more time within the open arms of the elevated plus maze (*p<0.05, t= 
2.269 df=12, cntl n=6, Crybb1-KD n=8), an effect that was more pronounced within the first 
5 min of this trial (**p<0.01, t= 3.634 df=12, cntl n=6, Crybb1-KD n=8).
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Figure 7. Proposed working model depicting activity-dependent regulation of Gomafu lncRNA 
in the mouse prefrontal cortex
Under basal conditions, Gomafu lncRNA associates with the PRC1 (BMI1) complex to 
mediate in cis repression of Crybb1, potentially through the histone ubiquitination mark. In 
response to an environmental stimulus, such as that triggered by the fear-conditioning 
paradigm, Gomafu lncRNA is significantly down-regulated, rapidly releasing BMI1 from 
the Crybb1 promoter and allowing its transcription, resulting in the up-regulation of Crybb1.
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